Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab versus placebo in children with severe uncontrolled asthma
NL-OMON60024Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Tezepelumab with Placebo (2 arms). Primary endpoint: Annualised asthma exacerbation rate. Started Apr 2024; status: completed.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON60024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60024.